Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Cash from Financing Activities data on file, last reported at $412.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 77887.15% year-over-year to $412.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.1 million (up 1584.03% YoY) and the FY2025 annual result came in at -$349.9 million, down 5974.14% from the prior year.
• Cash from Financing Activities rose to $412.6 million in Q1 2026, from -$218.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $412.6 million in Q1 2026 to a low of -$218.0 million in Q4 2025.
• A 5-year average of $10.4 million and a median of $529000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 5320.54% — and 2026, when it jumped 77887.15%.
• Tracing BCRX's Cash from Financing Activities over 5 years: stood at $4.2 million in 2022, then sank by 175.57% to -$3.2 million in 2023, then fell by 26.73% to -$4.0 million in 2024, then sank by 5320.54% to -$218.0 million in 2025, then surged by 289.28% to $412.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $412.6 million (Q1 2026), -$218.0 million (Q4 2025), and -$58.8 million (Q3 2025), per Business Quant data.